APA (7th ed.) Citation

H, L., K, R., MV, M., B, K., V, G., M, L., . . . R, H. (2024). Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting. Clinical lymphoma, myeloma & leukemia, 24(2), e40. https://doi.org/10.1016/j.clml.2023.10.003

Chicago Style (17th ed.) Citation

H, Ludwig, et al. "Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting." Clinical Lymphoma, Myeloma & Leukemia 24, no. 2 (2024): e40. https://doi.org/10.1016/j.clml.2023.10.003.

MLA (9th ed.) Citation

H, Ludwig, et al. "Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting." Clinical Lymphoma, Myeloma & Leukemia, vol. 24, no. 2, 2024, p. e40, https://doi.org/10.1016/j.clml.2023.10.003.